HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study.

AbstractBACKGROUND:
Experimentally, activated macrophages have been documented to induce vascular proliferation.
METHODS AND RESULTS:
In 21 patients (age 74+/-9 years) with extensive coronary artery disease not eligible for coronary artery bypass surgery, the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF, Molgramostim) on quantitatively assessed collateral flow was tested in a randomized, double-blind, placebo-controlled fashion. The study protocol consisted of an invasive collateral flow index (CFI) measurement immediately before intracoronary injection of 40 microg of GM-CSF (n=10) or placebo (n=11) and after a 2-week period with subcutaneous GM-CSF (10 microg/kg) or placebo, respectively. CFI was determined by simultaneous measurement of mean aortic pressure (P(ao), mm Hg), distal coronary occlusive pressure (P(occl), mm Hg; using intracoronary sensor guidewires), and central venous pressure (CVP, mm Hg): CFI=(P(occl)-CVP)/(P(ao)-CVP). CFI, expressing collateral flow during coronary occlusion relative to normal antegrade flow during vessel patency, changed from 0.21+/-0.14 to 0.31+/-0.23 in the GM-CSF group (P<0.05) and from 0.30+/-0.16 to 0.23+/-0.11 in the placebo group (P=NS). The treatment-induced difference in CFI was +0.11+/-0.12 in the GM-CSF group and -0.07+/-0.12 in the placebo group (P=0.01). ECG signs of myocardial ischemia during coronary balloon occlusion occurred in 9 of 10 patients before and 5 of 10 patients after GM-CSF treatment (P=0.04), whereas they were observed in 5 of 11 patients before and 8 of 11 patients after placebo (P=NS).
CONCLUSIONS:
This first clinical study investigating the potential of GM-CSF to improve collateral flow in patients with coronary artery disease documents its efficacy in a short-term administration protocol.
AuthorsC Seiler, T Pohl, K Wustmann, D Hutter, P A Nicolet, S Windecker, F R Eberli, B Meier
JournalCirculation (Circulation) Vol. 104 Issue 17 Pg. 2012-7 (Oct 23 2001) ISSN: 1524-4539 [Electronic] United States
PMID11673338 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Granulocyte-Macrophage Colony-Stimulating Factor
Topics
  • Aged
  • Angioplasty, Balloon, Coronary
  • Collateral Circulation (drug effects)
  • Coronary Angiography (methods)
  • Coronary Artery Disease (diagnosis, drug therapy, surgery)
  • Coronary Circulation (drug effects)
  • Double-Blind Method
  • Drug Eruptions (etiology)
  • Electrocardiography
  • Female
  • Fever (etiology)
  • Follow-Up Studies
  • Granulocyte-Macrophage Colony-Stimulating Factor (administration & dosage, adverse effects)
  • Hemodynamics (drug effects)
  • Humans
  • Injections, Subcutaneous
  • Male
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: